0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review

      1 , 2
      Expert Review of Endocrinology & Metabolism
      Informa UK Limited

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references113

          • Record: found
          • Abstract: not found
          • Article: not found

          2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

            The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

              In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.
                Bookmark

                Author and article information

                Journal
                Expert Review of Endocrinology & Metabolism
                Expert Review of Endocrinology & Metabolism
                Informa UK Limited
                1744-6651
                1744-8417
                July 04 2023
                May 08 2023
                July 04 2023
                : 18
                : 4
                : 271-282
                Affiliations
                [1 ]Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, Belgium
                [2 ]Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium
                Article
                10.1080/17446651.2023.2210673
                37154218
                b10d83c3-dd30-4fab-b45b-50149012c2ce
                © 2023
                History

                Comments

                Comment on this article